Anika Total Liab vs Total Current Liabilities Analysis

ANIK Stock  USD 16.97  0.46  2.64%   
Anika Therapeutics financial indicator trend analysis is way more than just evaluating Anika Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anika Therapeutics is a good investment. Please check the relationship between Anika Therapeutics Total Liab and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Total Liab vs Total Current Liabilities

Total Liab vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anika Therapeutics Total Liab account and Total Current Liabilities. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Anika Therapeutics' Total Liab and Total Current Liabilities is 0.95. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Anika Therapeutics, assuming nothing else is changed. The correlation between historical values of Anika Therapeutics' Total Liab and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Anika Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Liab i.e., Anika Therapeutics' Total Liab and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.95
Relationship DirectionPositive 
Relationship StrengthVery Strong

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Total Current Liabilities

Total Current Liabilities is an item on Anika Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Anika Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Anika Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' Selling General Administrative is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 120.31 this year, although the value of Tax Provision is projected to rise to (3.7 M).
 2021 2022 2023 2024 (projected)
Gross Profit82.9M93.6M103.1M108.2M
Total Revenue147.8M156.2M166.7M175.0M

Anika Therapeutics fundamental ratios Correlations

0.790.660.590.980.8-0.60.950.510.770.850.690.60.640.60.620.540.450.580.360.890.270.530.640.410.68
0.790.440.420.80.68-0.520.690.480.650.590.570.680.730.330.550.420.750.360.430.770.060.410.850.420.81
0.660.440.970.530.82-0.010.510.810.220.820.090.710.320.830.920.740.280.950.670.370.590.90.430.270.39
0.590.420.970.450.830.080.40.90.140.760.00.770.310.790.920.770.360.950.720.30.680.90.460.280.38
0.980.80.530.450.74-0.720.980.420.850.740.80.560.660.430.530.440.440.420.310.950.140.420.630.490.7
0.80.680.820.830.74-0.320.710.760.520.730.430.890.540.620.890.650.410.770.790.660.540.810.630.530.61
-0.6-0.52-0.010.08-0.72-0.32-0.71-0.01-0.96-0.14-0.95-0.18-0.580.1-0.030.19-0.280.12-0.09-0.850.440.15-0.46-0.25-0.63
0.950.690.510.40.980.71-0.710.360.830.710.810.460.520.410.50.390.240.390.270.930.150.410.480.510.56
0.510.480.810.90.420.76-0.010.360.190.590.080.750.280.540.860.670.440.770.70.330.560.790.480.380.4
0.770.650.220.140.850.52-0.960.830.190.370.940.350.640.140.230.030.360.110.230.93-0.220.080.570.30.69
0.850.590.820.760.740.73-0.140.710.590.370.220.570.440.860.690.820.380.820.280.520.530.710.430.170.46
0.690.570.090.00.80.43-0.950.810.080.940.220.250.57-0.050.14-0.130.23-0.060.190.93-0.27-0.030.480.480.61
0.60.680.710.770.560.89-0.180.460.750.350.570.250.620.430.820.660.630.650.80.480.440.730.740.490.69
0.640.730.320.310.660.54-0.580.520.280.640.440.570.620.250.270.210.820.270.330.67-0.080.120.880.180.98
0.60.330.830.790.430.620.10.410.540.140.86-0.050.430.250.640.660.220.930.340.240.60.660.28-0.140.25
0.620.550.920.920.530.89-0.030.50.860.230.690.140.820.270.640.730.310.840.820.410.60.940.480.470.39
0.540.420.740.770.440.650.190.390.670.030.82-0.130.660.210.660.730.350.750.310.180.660.840.280.260.26
0.450.750.280.360.440.41-0.280.240.440.360.380.230.630.820.220.310.350.270.30.410.030.20.90.090.86
0.580.360.950.950.420.770.120.390.770.110.82-0.060.650.270.930.840.750.270.60.240.670.840.360.080.32
0.360.430.670.720.310.79-0.090.270.70.230.280.190.80.330.340.820.310.30.60.350.450.70.570.480.42
0.890.770.370.30.950.66-0.850.930.330.930.520.930.480.670.240.410.180.410.240.35-0.010.260.660.520.71
0.270.060.590.680.140.540.440.150.56-0.220.53-0.270.44-0.080.60.60.660.030.670.45-0.010.710.070.26-0.08
0.530.410.90.90.420.810.150.410.790.080.71-0.030.730.120.660.940.840.20.840.70.260.710.320.460.21
0.640.850.430.460.630.63-0.460.480.480.570.430.480.740.880.280.480.280.90.360.570.660.070.320.30.92
0.410.420.270.280.490.53-0.250.510.380.30.170.480.490.18-0.140.470.260.090.080.480.520.260.460.30.25
0.680.810.390.380.70.61-0.630.560.40.690.460.610.690.980.250.390.260.860.320.420.71-0.080.210.920.25
Click cells to compare fundamentals

Anika Therapeutics Account Relationship Matchups

Anika Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets330.7M365.6M347.5M349.1M270.6M148.0M
Other Current Liab11.3M26.3M20.4M16.0M17.8M18.7M
Total Current Liabilities16.3M36.9M29.8M27.9M31.1M32.6M
Total Stockholder Equity288.4M272.4M287.1M285.6M212.3M120.9M
Property Plant And Equipment Net73.6M73.2M68.6M79.0M75.0M78.7M
Net Debt(136.1M)(74.9M)(75.1M)(55.4M)(43.8M)(46.0M)
Retained Earnings245.4M221.4M225.6M210.7M128.1M71.7M
Accounts Payable3.8M9.0M7.6M9.1M9.9M10.4M
Cash157.5M95.8M94.4M86.3M72.9M54.9M
Non Current Assets Total96.4M188.2M179.0M179.6M107.3M55.4M
Cash And Short Term Investments184.9M98.3M94.4M86.3M72.9M62.2M
Net Receivables23.1M24.1M29.8M34.6M36.0M37.8M
Common Stock Shares Outstanding14.4M14.2M14.6M14.6M14.7M12.7M
Liabilities And Stockholders Equity330.7M365.6M347.5M349.1M270.6M148.0M
Non Current Liabilities Total26.1M56.3M30.7M35.7M27.3M15.3M
Inventory22.0M46.2M36.0M39.8M46.4M48.7M
Other Current Assets1.4M8.8M16.6M17.7M8.1M8.5M
Other Stockholder Equity48.7M55.4M67.1M81.1M90.0M54.8M
Total Liab42.3M93.2M60.5M63.6M58.4M61.3M
Property Plant And Equipment Gross73.6M73.2M47.6M48.3M122.6M128.8M
Total Current Assets235.7M177.4M168.5M169.5M163.3M92.6M
Accumulated Other Comprehensive Income(5.9M)(4.5M)(5.7M)(6.4M)(5.9M)(6.2M)
Non Currrent Assets Other7.5M15.4M20.3M17.2M18.7M19.6M
Common Stock Total Equity147K142K143K144K167.9K139.2K
Short Term Investments70.0M27.5M2.5M34.6M39.8M41.8M
Other Assets(1.4M)38.0M20.3M18.7M21.5M22.5M
Property Plant Equipment50.8M50.6M47.6M48.3M55.5M32.3M
Other Liab4.7M35.5M11.4M6.8M6.2M8.1M
Good Will7.7M8.4M7.8M7.3M7.6M8.0M
Intangible Assets7.6M91.2M82.4M74.6M4.6M4.4M
Net Tangible Assets294.5M193.7M216.2M232.4M267.3M227.7M
Retained Earnings Total Equity245.4M221.4M225.6M210.7M242.3M149.3M
Capital Surpluse48.7M55.4M67.1M81.1M73.0M52.5M
Deferred Long Term Liab4.3M11.9M10.2M6.4M7.4M7.2M
Non Current Liabilities Other357K23.6M1.3M398K404K383.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.